The OECD report illustrates the paradox of governments advocating for transparency in medicine pricing, yet choosing secretive agreements with pharmaceutical companies to secure lower prices.
Miquel Serra notes that the OECD report highlights the contradictions in medicine purchasing policies, which reflect a tragedy of the commons where individual interests undermine collective benefits.
Collection
[
|
...
]